O

Onxeo SA
PAR:ALONX

Watchlist Manager
Onxeo SA
PAR:ALONX
Watchlist
Price: 0.272 EUR 0.74% Market Closed
Market Cap: 30.2m EUR

Relative Value

There is not enough data to reliably calculate the relative value of ALONX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALONX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
20.9
Median 5Y
20.9
Industry
8
Forward
0.5
vs History
vs Industry
Median 3Y
-1.5
Median 5Y
-1.5
Industry
23.5
Forward
0.7
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3.2
Industry
21.9
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.6
Industry
24.3
vs History
vs Industry
Median 3Y
1.4
Median 5Y
1.4
Industry
3.2
vs History
vs Industry
Median 3Y
16.9
Median 5Y
16.9
Industry
8.1
Forward
0.4
vs History
vs Industry
Median 3Y
26.2
Median 5Y
26.2
Industry
10.1
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.4
Industry
5.9
vs History
vs Industry
Median 3Y
-1.4
Median 5Y
-1.4
Industry
6.2
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-2.6
Industry
7.7
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-2.5
Industry
6.3
vs History
vs Industry
Median 3Y
1
Median 5Y
1
Industry
5.6

Multiples Across Competitors

ALONX Competitors Multiples
Onxeo SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Onxeo SA
PAR:ALONX
30.2m EUR 20.9 -1.5 -1.4 -1.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 33.9 58.5 60.1
P/S Multiple
Revenue Growth P/S to Growth
FR
O
Onxeo SA
PAR:ALONX
Average P/S: 3 069 857.8
20.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 766 261.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 086.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
P/E Multiple
Earnings Growth PEG
FR
O
Onxeo SA
PAR:ALONX
Average P/E: 191.1
Negative Multiple: -1.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
O
Onxeo SA
PAR:ALONX
Average EV/EBITDA: 40.2
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
O
Onxeo SA
PAR:ALONX
Average EV/EBIT: 46.4
Negative Multiple: -1.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A